Key Takeaways SKYE stock plunged 60% after nimacimab missed the primary goal in its phase IIa obesity study.The nimacimab/Wegovy combo showed greater weight loss and no safety concerns through the initial 26 weeks.Enrollment for the study's 26-week extension phase is complete, with readout planned for early 2026.Shares of Skye Bioscience (SKYE) crashed 60% on Monday after the company failed to meet the key goal in a mid-stage proof-of-concept study of its only pipeline candidate, nimacimab, for obesity.The ...